Endocrine effects of naloxone-induced opiate receptor blockade

J. E. Morley, N. G. Baranetsky, T. D. Wingert, H. E. Carlson, J. M. Hershman, S. Melmed, S. R. Levin, Kay Jamison, R. Weitzman, R. J. Chang, A. A. Varner

Research output: Contribution to journalArticle

Abstract

To test the effect of opiate receptor blockade on hormone release in man, the authors administered 10 mg naloxone i.v. to 8 normal subjects and compared the results with those found after saline infusion. Naloxone produced a rise in serum cortisol (P <0.01), LH (P <0.01), FSH (P <0.05), and insulin (P <0.05) levels but did not alter serum GH, PRL, TSH, arginine vasopressin, glucagon, T 3, or T 4. Naloxone had no effect on GH levels in 2 subjects with active acromegaly or on TSH levels in 6 subjects with primary hypothyroidism. In dynamic pituitary function testing, naloxone diminished the GH response to arginine (P <0.05) without altering the PRL response; naloxone augmented the PRL response to TRH (P <0.025) without affecting the TSH response. Naloxone did not significantly alter GH or PRL response to L-dopa. Naloxone enhanced the increment in serum cortisol induced by the stress of gastroscopy without changing the GH or PRL response. Naloxone increased glucose response areas (P <0.05) after an i.v. glucose bolus and raised the maximum plasma glucose level (P <0.05) without altering the rate of glucose disappearance. Glucagon and insulin responses to glucose and arginine were not altered by naloxone. Psychological testing showed that naloxone altered performance on the Graham-Kendall memory Memory Designs test in half of the subjects studied. There were no significant differences between saline and naloxone trials on the Profile of Mood States questionnaire or the mood-anxiety scale. Together with subjective reports from 2 of the subjects that naloxone decreased their ability to concentrate, these data suggest that opiate receptors may play a role in short term memory. Specific opiate receptor blockade with naloxone has definite endocrine and metabolic effects, suggesting endogenous opioid modulation of secretion of some of these hormones. Since these effects of naloxone are not always complementary to those of opiates, exogenous opiates may also act on separate receptors which are not blocked by naloxone.

Original languageEnglish (US)
Pages (from-to)251-257
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume50
Issue number2
StatePublished - 1980
Externally publishedYes

Fingerprint

Opioid Receptors
Naloxone
Opiate Alkaloids
Glucose
Glucagon
Data storage equipment
Arginine
Hydrocortisone
Serum
Hormones
Insulin
Gastroscopy
Aptitude
Acromegaly
Arginine Vasopressin
Neuropsychological Tests
Levodopa
Testing
Hypothyroidism
Short-Term Memory

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Morley, J. E., Baranetsky, N. G., Wingert, T. D., Carlson, H. E., Hershman, J. M., Melmed, S., ... Varner, A. A. (1980). Endocrine effects of naloxone-induced opiate receptor blockade. Journal of Clinical Endocrinology and Metabolism, 50(2), 251-257.

Endocrine effects of naloxone-induced opiate receptor blockade. / Morley, J. E.; Baranetsky, N. G.; Wingert, T. D.; Carlson, H. E.; Hershman, J. M.; Melmed, S.; Levin, S. R.; Jamison, Kay; Weitzman, R.; Chang, R. J.; Varner, A. A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 50, No. 2, 1980, p. 251-257.

Research output: Contribution to journalArticle

Morley, JE, Baranetsky, NG, Wingert, TD, Carlson, HE, Hershman, JM, Melmed, S, Levin, SR, Jamison, K, Weitzman, R, Chang, RJ & Varner, AA 1980, 'Endocrine effects of naloxone-induced opiate receptor blockade', Journal of Clinical Endocrinology and Metabolism, vol. 50, no. 2, pp. 251-257.
Morley JE, Baranetsky NG, Wingert TD, Carlson HE, Hershman JM, Melmed S et al. Endocrine effects of naloxone-induced opiate receptor blockade. Journal of Clinical Endocrinology and Metabolism. 1980;50(2):251-257.
Morley, J. E. ; Baranetsky, N. G. ; Wingert, T. D. ; Carlson, H. E. ; Hershman, J. M. ; Melmed, S. ; Levin, S. R. ; Jamison, Kay ; Weitzman, R. ; Chang, R. J. ; Varner, A. A. / Endocrine effects of naloxone-induced opiate receptor blockade. In: Journal of Clinical Endocrinology and Metabolism. 1980 ; Vol. 50, No. 2. pp. 251-257.
@article{3e3adb16f00543a48fd5932de0a57e2d,
title = "Endocrine effects of naloxone-induced opiate receptor blockade",
abstract = "To test the effect of opiate receptor blockade on hormone release in man, the authors administered 10 mg naloxone i.v. to 8 normal subjects and compared the results with those found after saline infusion. Naloxone produced a rise in serum cortisol (P <0.01), LH (P <0.01), FSH (P <0.05), and insulin (P <0.05) levels but did not alter serum GH, PRL, TSH, arginine vasopressin, glucagon, T 3, or T 4. Naloxone had no effect on GH levels in 2 subjects with active acromegaly or on TSH levels in 6 subjects with primary hypothyroidism. In dynamic pituitary function testing, naloxone diminished the GH response to arginine (P <0.05) without altering the PRL response; naloxone augmented the PRL response to TRH (P <0.025) without affecting the TSH response. Naloxone did not significantly alter GH or PRL response to L-dopa. Naloxone enhanced the increment in serum cortisol induced by the stress of gastroscopy without changing the GH or PRL response. Naloxone increased glucose response areas (P <0.05) after an i.v. glucose bolus and raised the maximum plasma glucose level (P <0.05) without altering the rate of glucose disappearance. Glucagon and insulin responses to glucose and arginine were not altered by naloxone. Psychological testing showed that naloxone altered performance on the Graham-Kendall memory Memory Designs test in half of the subjects studied. There were no significant differences between saline and naloxone trials on the Profile of Mood States questionnaire or the mood-anxiety scale. Together with subjective reports from 2 of the subjects that naloxone decreased their ability to concentrate, these data suggest that opiate receptors may play a role in short term memory. Specific opiate receptor blockade with naloxone has definite endocrine and metabolic effects, suggesting endogenous opioid modulation of secretion of some of these hormones. Since these effects of naloxone are not always complementary to those of opiates, exogenous opiates may also act on separate receptors which are not blocked by naloxone.",
author = "Morley, {J. E.} and Baranetsky, {N. G.} and Wingert, {T. D.} and Carlson, {H. E.} and Hershman, {J. M.} and S. Melmed and Levin, {S. R.} and Kay Jamison and R. Weitzman and Chang, {R. J.} and Varner, {A. A.}",
year = "1980",
language = "English (US)",
volume = "50",
pages = "251--257",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Endocrine effects of naloxone-induced opiate receptor blockade

AU - Morley, J. E.

AU - Baranetsky, N. G.

AU - Wingert, T. D.

AU - Carlson, H. E.

AU - Hershman, J. M.

AU - Melmed, S.

AU - Levin, S. R.

AU - Jamison, Kay

AU - Weitzman, R.

AU - Chang, R. J.

AU - Varner, A. A.

PY - 1980

Y1 - 1980

N2 - To test the effect of opiate receptor blockade on hormone release in man, the authors administered 10 mg naloxone i.v. to 8 normal subjects and compared the results with those found after saline infusion. Naloxone produced a rise in serum cortisol (P <0.01), LH (P <0.01), FSH (P <0.05), and insulin (P <0.05) levels but did not alter serum GH, PRL, TSH, arginine vasopressin, glucagon, T 3, or T 4. Naloxone had no effect on GH levels in 2 subjects with active acromegaly or on TSH levels in 6 subjects with primary hypothyroidism. In dynamic pituitary function testing, naloxone diminished the GH response to arginine (P <0.05) without altering the PRL response; naloxone augmented the PRL response to TRH (P <0.025) without affecting the TSH response. Naloxone did not significantly alter GH or PRL response to L-dopa. Naloxone enhanced the increment in serum cortisol induced by the stress of gastroscopy without changing the GH or PRL response. Naloxone increased glucose response areas (P <0.05) after an i.v. glucose bolus and raised the maximum plasma glucose level (P <0.05) without altering the rate of glucose disappearance. Glucagon and insulin responses to glucose and arginine were not altered by naloxone. Psychological testing showed that naloxone altered performance on the Graham-Kendall memory Memory Designs test in half of the subjects studied. There were no significant differences between saline and naloxone trials on the Profile of Mood States questionnaire or the mood-anxiety scale. Together with subjective reports from 2 of the subjects that naloxone decreased their ability to concentrate, these data suggest that opiate receptors may play a role in short term memory. Specific opiate receptor blockade with naloxone has definite endocrine and metabolic effects, suggesting endogenous opioid modulation of secretion of some of these hormones. Since these effects of naloxone are not always complementary to those of opiates, exogenous opiates may also act on separate receptors which are not blocked by naloxone.

AB - To test the effect of opiate receptor blockade on hormone release in man, the authors administered 10 mg naloxone i.v. to 8 normal subjects and compared the results with those found after saline infusion. Naloxone produced a rise in serum cortisol (P <0.01), LH (P <0.01), FSH (P <0.05), and insulin (P <0.05) levels but did not alter serum GH, PRL, TSH, arginine vasopressin, glucagon, T 3, or T 4. Naloxone had no effect on GH levels in 2 subjects with active acromegaly or on TSH levels in 6 subjects with primary hypothyroidism. In dynamic pituitary function testing, naloxone diminished the GH response to arginine (P <0.05) without altering the PRL response; naloxone augmented the PRL response to TRH (P <0.025) without affecting the TSH response. Naloxone did not significantly alter GH or PRL response to L-dopa. Naloxone enhanced the increment in serum cortisol induced by the stress of gastroscopy without changing the GH or PRL response. Naloxone increased glucose response areas (P <0.05) after an i.v. glucose bolus and raised the maximum plasma glucose level (P <0.05) without altering the rate of glucose disappearance. Glucagon and insulin responses to glucose and arginine were not altered by naloxone. Psychological testing showed that naloxone altered performance on the Graham-Kendall memory Memory Designs test in half of the subjects studied. There were no significant differences between saline and naloxone trials on the Profile of Mood States questionnaire or the mood-anxiety scale. Together with subjective reports from 2 of the subjects that naloxone decreased their ability to concentrate, these data suggest that opiate receptors may play a role in short term memory. Specific opiate receptor blockade with naloxone has definite endocrine and metabolic effects, suggesting endogenous opioid modulation of secretion of some of these hormones. Since these effects of naloxone are not always complementary to those of opiates, exogenous opiates may also act on separate receptors which are not blocked by naloxone.

UR - http://www.scopus.com/inward/record.url?scp=0018905309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018905309&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 251

EP - 257

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -